NCT00251303View on ClinicalTrials.gov

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Obsessive-Compulsive DisorderAutism Spectrum DisorderAutismAsperger DisorderDevelopmental Disorder
Interventions
DRUG

Riluzole

Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.

DRUG

Placebo

Capsules matched active drug in appearance.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH

NCT00251303 - Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders | Biotech Hunter | Biotech Hunter